Myeloma Patients Europe (MPE) is an umbrella organisation of patient groups representing myeloma and AL amyloidosis patients. MPE currently has 48 members in 30 European countries.
The Myeloma Access Atlas is an online platform designed to provide myeloma and AL amyloidosis patient advocates with information needed to work effectively on access issues. It provides country specific and comparative information on European health systems, including data on system performance (as well as stakeholder perceptions on this topic) and on access to treatment and care.
Through the Myeloma Access Atlas, MPE has worked with industry, physicians and its members to map national access to 26 drugs and drug combinations approved by the European Medicines Agency (EMA) across geographical Europe. This presentation will focus on the process and results of this mapping exercise, alongside key findings on European access inequalities. MPE ideas for solutions to address these inequalities will also be presented.